By Vince Paolizzi, Peli BioThermal

Published in: Pharmaceutical online

Published on: May 11, 2022

Closing Paragraph: Ultimately, the increasing complex protocols that attend modern clinical trials, coupled with the needs and preferences of the patients involved and the logistical challenges introduced by the pandemic, have made direct-to- and direct-from-patient shipping crucial tools for providers and trial sponsors alike. Data to date shows that DCTs boast a somewhat higher enrollment rate than traditional clinical trials; retention and compliance among patients is also frequently improved by offering home health services in place of a trial site. As the demand for temperature-sensitive samples and therapeutics continues to rise, facilitating these solutions through a supplier with the expertise and experience needed to grow alongside development is integral to advancing the biopharmaceutical industry’s impact and reach.

Advance Stability Knowledge

Would you like to see a particular publication, guidance, organization, supplier, event, or career opportunity on StabilityHub? Contact us with your suggestion!